Saliva gland test could diagnose Parkinson's disease
RELATED
WASHINGTON: Testing a portion of a person's salivary gland may help
diagnose Parkinson's disease for the very first time, says a new
research.
Parkinson's affects mainly people over 50 years who suffer symptoms such as slowness, which may impede efforts to walk or to stand up, stiffness of muscles (rigidity) and tremors.
"There is currently no diagnostic test for Parkinson's disease," says study author Charles Adler, neurologist with Mayo Clinic in Arizona, US.
"We have previously shown in autopsies of Parkinson's patients that the abnormal proteins associated with Parkinson's are consistently found in the submandibular saliva glands, found under the lower jaw," adds Adler.
"Making a diagnosis in living patients is a big step forward in our effort to understand and better treat patients," says Adler, according to a Mayo Clinic statement.
The study involved a group of people averaging 68 years who had Parkinson's for an average of 12 years. They had responded to Parkinson's medication and would not have known saliva gland disorders.
Biopsies were taken of two different saliva glands: the submandibular gland and the minor saliva glands in the lower lip.
The surgical team was led by Michael Hinni and David Lott, at the Mayo Clinic and the biopsied tissues were tested for evidence of the abnormal Parkinson's protein by study co-author Thomas Beach, with Banner Sun Health Research Institute.
"This procedure will provide a much more accurate diagnosis of Parkinson's disease than what is now available," Beach says.
"One of the greatest potential impacts of this finding is on clinical trials, as at the present time some patients entered into Parkinson's clinical trials do not necessarily have Parkinson's disease and this is a big impediment to testing new therapies," Beach says.
The abnormal Parkinson's protein was detected in nine of the 11 patients who had enough tissue to study. Although Parkinson's disease can't be cured, medications may markedly improve symptoms.
These findings will be presented at the American Academy of Neurology's annual meeting in San Diego in March.
Parkinson's affects mainly people over 50 years who suffer symptoms such as slowness, which may impede efforts to walk or to stand up, stiffness of muscles (rigidity) and tremors.
"There is currently no diagnostic test for Parkinson's disease," says study author Charles Adler, neurologist with Mayo Clinic in Arizona, US.
"We have previously shown in autopsies of Parkinson's patients that the abnormal proteins associated with Parkinson's are consistently found in the submandibular saliva glands, found under the lower jaw," adds Adler.
"Making a diagnosis in living patients is a big step forward in our effort to understand and better treat patients," says Adler, according to a Mayo Clinic statement.
The study involved a group of people averaging 68 years who had Parkinson's for an average of 12 years. They had responded to Parkinson's medication and would not have known saliva gland disorders.
Biopsies were taken of two different saliva glands: the submandibular gland and the minor saliva glands in the lower lip.
The surgical team was led by Michael Hinni and David Lott, at the Mayo Clinic and the biopsied tissues were tested for evidence of the abnormal Parkinson's protein by study co-author Thomas Beach, with Banner Sun Health Research Institute.
"This procedure will provide a much more accurate diagnosis of Parkinson's disease than what is now available," Beach says.
"One of the greatest potential impacts of this finding is on clinical trials, as at the present time some patients entered into Parkinson's clinical trials do not necessarily have Parkinson's disease and this is a big impediment to testing new therapies," Beach says.
The abnormal Parkinson's protein was detected in nine of the 11 patients who had enough tissue to study. Although Parkinson's disease can't be cured, medications may markedly improve symptoms.
These findings will be presented at the American Academy of Neurology's annual meeting in San Diego in March.
